Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $188 saying today’s Phase III Apollo results confirm patisiran’s superior efficacy compared to Ionis Pharmaceuticals’ (IONS) inotsersen. Alnylam in afternoon trading is up 12%, or $14.71, to $135.80. Patisiran is also safer with almost no treatment-related serious adverse events except diarrhea, and fewer discontinuations and deaths than placebo, Tenthoff tells investors in an afternoon research note. The analyst reiterates an Overweight rating on Alnylam shares.